OPKO Health, Inc.

What they do

OPKO operates through two main segments: BioReference Health (diagnostics) and Pharmaceuticals (including proprietary products and Biologics). Its only approved proprietary pharmaceuticals are Rayaldee and NGENLA. It develops a pipeline of multispecific antibodies and metabolic therapies through ModeX and OPKO Biologics.

Revenue drivers

• BioReference Health — Provides diagnostic testing services; historically the largest revenue contributor, though COVID-19 testing has declined significantly.
• Pharmaceutical products — Includes Rayaldee and NGENLA sales, which are approved in multiple territories but have historically generated limited revenue.
• Other licensing and collaboration revenue — Includes payments from partnerships such as the BARDA-funded COVID-19 program and co-development agreements like with Entera Bio.

Recent performance

Second quarter 2026 revenue was $163.6 million, up from $124.2 million in the prior quarter, but down from $151.7 million in the year-ago quarter. The company reported a net loss of $225.68 million for 2025 and has not been profitable recently, with negative operating cash flow of $178.5 million in 2025. Cash and equivalents were $300.8 million as of June 30, 2026, with negligible long-term debt ($1.8 million). Quarterly revenue has been volatile: $151.7M (Sep-2025), $148.5M (Dec-2025), $124.2M (Mar-2026), and $163.6M (Jun-2026).

Strategy

OPKO is advancing a pipeline of novel multispecific antibodies through ModeX, including in vivo CAR T programs and T-cell engagers, with several Phase 1 trials underway. It initiated a Phase 1/2a study of OPK-88006, a dual GLP-1/Glucagon agonist for MASH, and plans to advance OPK8801001, a long-acting growth hormone receptor antagonist, to clinical trials. The company is also leveraging partnerships, such as with BARDA and Entera Bio, to fund and co-develop programs. It continues to focus on commercializing Rayaldee and NGENLA while managing costs and cash flow.

Risks

• History of losses — The company has a history of operating losses, particularly excluding COVID-19 test revenues, and may not achieve profitability in the near future.
• Dependence on few products — Rayaldee and NGENLA are the only approved proprietary drugs; if they fail commercially, revenue may remain limited.
• Clinical trial risk — Several pipeline candidates (MDX2003, MDX2301, OPK-88006) are in early Phase 1 trials and may fail to show safety or efficacy.
• Funding requirements — The company may need additional funding to support R&D and operations; as of December 31, 2025, it noted potential cash needs.

Outlook

Management expects to report initial data from MDX2001 and MDX2004 in the first half of 2027. The MDX2301 Phase 1 trial is expected to complete enrollment in Q3 2026, with early data late 2026 or early 2027. OPK-88006 Phase 1/2a study has begun enrolling in the US, and OPK8801001 is planned to advance to clinical trials by end of 2026.